Navigation Links
Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
Date:10/12/2010

EAST NORRITON, Pa., Oct. 12 /PRNewswire-FirstCall/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced that it will host an Analyst and Investor Meeting on Wednesday, October 27, 2010 in New York, New York. Tengion's management team will provide an update on the Company's product development portfolio and upcoming corporate milestones, and will expand on recently presented data from the Neo-Kidney Augment™ program.

The live webcast of the event will be available under the Investors section of the Company's website at www.tengion.com and will begin at 1:00 pm ET and will end at approximately 3:00 pm ET. To participate in the webcast, please pre-register at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=218965&eventID=3420638.

An archive of the event will be available on the Company's website.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. Tengion commenced a Phase I clinical trial in the first half of 2010 for its lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder and is in preclinical development of its Neo-Kidney Augment™. Tengion has worldwide rights to its product candidates.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
2. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
3. Tengion Announces Second Closing of Series C Financing
4. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
5. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
6. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
7. Tengion Appoints A. Brian Davis Chief Financial Officer
8. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
9. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
10. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
11. Anesiva Announces Second Quarter 2008 Financial Results and Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017   VWR ... of product and service solutions to laboratory ... has acquired EPL Archives, Inc., an international ... the entire regulated product research, development and ... storage and ancillary services. EPL Archives is ...
(Date:3/22/2017)... ... ... Okyanos Cell Therapy has announced Tallahassee, FL will be the next destination ... Therapy: The Next Phase in the Evolution of Medicine.” As the Bahamas’ first fully ... Act, Okyanos maintains a mission to help “no-option” patients and those with serious, ...
(Date:3/22/2017)... ... March 21, 2017 , ... Benchworks CEO Thad L. Bench ... on March 23-24 in San Diego. The event is a gathering of executive ... , Benchworks Vice President Christian Meyer will also participate in the forum. Participants will ...
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced the ... be held on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. The ... Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces a ...
Breaking Biology Technology:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
Breaking Biology News(10 mins):